LFCR FY2025 EPS Forecast Increased by Barrington Research

Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Equities researchers at Barrington Research increased their FY2025 earnings per share (EPS) estimates for shares of Lifecore Biomedical in a research note issued to investors on Wednesday, January 8th. Barrington Research analyst M. Petusky now anticipates that the company will earn ($0.98) per share for the year, up from their prior forecast of ($0.99). The consensus estimate for Lifecore Biomedical’s current full-year earnings is ($0.99) per share. Barrington Research also issued estimates for Lifecore Biomedical’s FY2026 earnings at ($0.60) EPS and FY2027 earnings at ($0.40) EPS.

A number of other brokerages have also recently issued reports on LFCR. Craig Hallum boosted their price objective on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 22nd. Stephens reissued an “equal weight” rating and issued a $6.00 price target on shares of Lifecore Biomedical in a report on Friday, January 3rd.

Lifecore Biomedical Stock Performance

Shares of LFCR stock opened at $6.29 on Friday. The stock has a market cap of $232.89 million, a PE ratio of 78.63 and a beta of 0.98. The stock has a 50-day moving average of $7.05 and a 200-day moving average of $5.82. The company has a debt-to-equity ratio of 12.90, a current ratio of 1.83 and a quick ratio of 0.80. Lifecore Biomedical has a one year low of $3.68 and a one year high of $8.90.

Lifecore Biomedical (NASDAQ:LFCR) last released its earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%.

Insider Activity

In related news, CEO Paul Josephs acquired 17,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The shares were acquired at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the acquisition, the chief executive officer now directly owns 559,717 shares in the company, valued at approximately $3,212,775.58. The trade was a 3.13 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 28.21% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lifecore Biomedical

Large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new position in shares of Lifecore Biomedical during the 2nd quarter worth approximately $327,000. Rhumbline Advisers boosted its holdings in Lifecore Biomedical by 1,668.5% during the second quarter. Rhumbline Advisers now owns 26,899 shares of the company’s stock worth $138,000 after purchasing an additional 25,378 shares during the last quarter. Renaissance Technologies LLC bought a new position in Lifecore Biomedical in the second quarter valued at $56,000. DCF Advisers LLC increased its stake in Lifecore Biomedical by 2.1% in the 2nd quarter. DCF Advisers LLC now owns 290,684 shares of the company’s stock valued at $1,491,000 after buying an additional 6,000 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in Lifecore Biomedical by 87.3% during the 2nd quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock worth $1,540,000 after buying an additional 139,887 shares in the last quarter. Institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.